Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase II trial of tisagenlecleucel in first-line high risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy

Principal Investigator: Twist, Clare J

An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies (VICC HEM1755)

Principal Investigator: Torka, Pallawi

NRG-GU007,RANDOMIZED PHASE II TRIAL OF NIRAPARIB WITH STANDARD COMBINATION RADIOTHERAPY AND ANDROGEN DEPRIVATION THERAPY (ADT) IN HIGH RISK PROSTATE CANCER (WITH INITIAL PHASE I) (NADIR*)
*Randomized Phase II Trial of Niraparib With Standard Combination…

Principal Investigator: Kuettel, Michael R

Phase II study of short course FOLFOX chemotherapy with either Nivolumab or Nivolumab + Radiation in the first line treatment of metastatic or unresectable gastroesophageal cancers (BMS Protocol CA209-76L).

Principal Investigator: Mukherjee, Sarbajit

PUMA-NER-5201, An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations

Principal Investigator: Fountzilas, Christos

A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients with Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Principal Investigator: Odunsi, Adekunle O

A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Principal Investigator: Elshoury, Amro

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Principal Investigator: Twist, Clare J

Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Principal Investigator: Thompson, James E

A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination with Azacitidine in Patients with Hematological Malignancies

Principal Investigator: Wang, Eunice S

(COG ANBL1821) A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Principal Investigator: Twist, Clare J

NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study

Principal Investigator: Griffiths, Elizabeth A

MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Principal Investigator: Levine, Ellis G

Endobronchial Ultrasound Transbronchial Needle Guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer in the Central Airway

Principal Investigator: Ivanick, Nathaniel M

Photoacoustic Imaging of Human Breast

Principal Investigator: Bonaccio, Ermelinda

(COG AHEP1531) Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Principal Investigator: Twist, Clare J

(A081801)Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC:ALCHEMIST Chemo-IO

Principal Investigator: Yau, Edwin H

An Open-label, Multicenter, Phase 1b Study of JNJ-74494550 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

(AAML1831) A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations

Principal Investigator: Twist, Clare J

An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2-Breast Cancer with an ESR1 Mutation

Principal Investigator: O'Connor, Tracey L

A phase 1, open-label, multiple-ascending dose study to investigate the safety,
pharmacokinetics, pharmacodynamics, and preliminary efficacy of KD033 in subjects with metastatic or locally advanced solid tumors

Principal Investigator: Puzanov, Igor

FUSION FPX-01-01 A Phase 1 Study of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumours

Principal Investigator: Puzanov, Igor

A RANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN, CTEP-SUPPLIED BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN AND…

Principal Investigator: Lele, Shashikant B

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic…

Principal Investigator: Griffiths, Elizabeth A

Phase 1/1b Trial of Talazoparib and Gemtuzumab ozogamicin in Adult Patients with Relapsed and/or Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S